Why a Reproducibility Review Reaches Back Into Procurement
A reproducibility review rarely opens with the manuscript. It opens with a question that most authors never anticipate: if another group ordered the same catalogue line, in the same month, from the same supplier, would they be handling a genuinely comparable material? The honest answer depends on two chains of custody rather than one. The supplier’s chain covers synthesis, analytical testing, documentation and dispatch. The purchaser’s chain covers receipt, storage, handling, COSHH assessment and record-keeping. A weakness in either chain breaks the link, and reviewers are increasingly competent at spotting which one gave way.
Research-use-only supply is built around that division of labour. Research Sciences, the UK supplier behind the current catalogue, states plainly that its materials are strictly for controlled laboratory and analytical research and are not medicines, medical devices, injectables, treatments or food supplements under UK law. The same position runs through its product pages and FAQs: not for human or veterinary use, not for consumption, administration or clinical application, and not supplied for therapeutic, clinical or diagnostic purposes. A researcher who treats RUO status as a label to be acknowledged at checkout, rather than an instruction that shapes the whole workflow, creates the first reproducibility risk before a single vial is opened.
The supplier’s side of the bargain is documentation. Research Sciences publishes lines such as ≥99% verified purity, “CoAs Janoshik Analytical Reports” and a testing framework described as covering purity, identity, heavy metals and endotoxin evaluation. Those are the shop’s published statements at the time of writing, not independently audited figures, and they should be reconfirmed on the live site and — far more importantly — against the certificate of analysis (CoA) issued for the specific batch in hand. Catalogue examples include BPC-157 10mg, TB-500 5mg, Ipamorelin 5mg, CJC-1295 (No DAC) 5mg, GHK-Cu 50mg, Tesamorelin 5mg and MT-1 10mg, alongside laboratory accessories such as a Storage Container and 10ml Mixing Water. None of those listings, on its own, tells a reviewer anything about how the material was kept after it arrived.
That is the purchaser’s half, and it is the half a review panel can actually interrogate. Procurement records, storage logs, COSHH paperwork and handling notes are the evidence a laboratory generates itself; they cannot be outsourced to a supplier and they cannot be reconstructed after the fact. A department preparing for scrutiny should therefore treat goods-in as the start of the audit, not the end of the purchase.
COSHH Sits With the Receiving Laboratory, Not the Supplier
The Control of Substances Hazardous to Health Regulations place the assessment duty on the employer — in practice, the laboratory or institution that takes receipt of the material. A RUO peptide arriving with a CoA is not thereby exempt from COSHH. Before the first weigh-out or reconstitution, the purchaser must establish whether the substance can be handled within existing generic controls or requires a substance-specific assessment. This is an internal judgement about the laboratory’s own environment, and no supplier can make it on the purchaser’s behalf.
What a substance-specific assessment should capture
A defensible assessment normally records the hazard information available for the material, the quantities likely to be held on site, the physical form and the reasonably foreseeable exposure routes in a laboratory setting — inhalation of lyophilised powder during handling, dermal contact, and inadvertent ingestion through poor technique. It should specify containment arrangements, personal protective equipment, spill and decontamination procedures, waste routes, storage segregation and a review date. Where a safety data sheet is available it should be attached; where it is not, the material should be treated conservatively and that reasoning written down. It is also worth noting in the assessment that, per the supplier’s FAQs, peptides contain trace amounts of mannitol as an excipient, since a bulking agent changes how a powder behaves when it is disturbed.
Storage, freeze–thaw and the record a reviewer will ask for
The handling guidance published by Research Sciences describes lyophilised peptides stored at −20°C or below, sealed with desiccant and protected from moisture, heat and light, with repeated freeze–thaw cycles avoided. Reconstituted material is characterised as less stable and intended for short-term storage at 2–8°C in a laboratory context. Purchasers should log receipt dates, storage location, temperature excursions, the date each vial is opened and, for in-vitro work, the diluent volume and target concentration prepared. The shop’s free reconstitution calculator is offered for laboratory research use only and must never be applied to human or veterinary dosing. Recording that the calculator was used, and for which assay, turns a routine calculation into auditable evidence.
Documentation, Traceability and the Checks Before Release
Batch-level documentation is where supplier and purchaser records must meet. The FAQs state that every compound is supplied with an HPLC CoA covering purity and identity, and that restocked products may carry the same Internal Test Reference (ITR) as earlier stock. That distinction matters: an ITR links a vial to associated sample testing reports, but it does not confirm that separate deliveries came from the same production lot or were independently tested separately. Vial cap colours, which may vary, are not an indicator of identity, analytical quality or manufacturing origin. The label reference combines SKU and expiry — for example BPC10-03/27 — and quoting that reference when contacting the shop about documentation is the quickest route to the correct certificate.
Researchers auditing their own supply therefore need a reconciliation step before material is released to a study: label reference matched to the CoA in hand, identity and stated purity checked against the protocol, and the certificate filed with the batch record rather than with the purchase order. Laboratories comparing documentation practices across suppliers often review the Peptides uk catalogue maintained by Research Sciences, where supported products are listed alongside their analytical documentation. That exercise is more useful than it first appears, because it forces a department to state in writing what it will accept as adequate evidence before a vial enters a controlled experiment.
Procurement practicalities also feed the audit trail. The shop states that orders are dispatched the next working day by Royal Mail Tracked 24, with delivery times described as estimates that may vary in peak periods, and that it does not accept card payments, using Pay-By-Bank or Open Banking arrangements through providers such as Wallid instead. Returns are not accepted once goods are dispatched, with refunds limited to damage, incorrect supply or quality issues under the published policy. None of those points are scientific, but each leaves a paper trail that should be filed alongside the technical records. Finally, the FAQs confirm the shop does not supply blended peptides and recommends buying individual compounds and combining them only within a controlled experimental design — a position that aligns neatly with a reviewer’s expectation that each variable in a preparation be separately documented.
Seattle UX researcher now documenting Arctic climate change from Tromsø. Val reviews VR meditation apps, aurora-photography gear, and coffee-bean genetics. She ice-swims for fun and knits wifi-enabled mittens to monitor hand warmth.